← Back to Clinical Trials
Recruiting NCT03916302

NCT03916302 Pulmonary Embolism WArsaw REgistry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03916302
Status Recruiting
Phase
Sponsor Medical University of Warsaw
Condition Acute Pulmonary Embolism
Study Type OBSERVATIONAL
Enrollment 1,500 participants
Start Date 2008-01-01
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,500 participants in total. It began in 2008-01-01 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Initiated in January 2008, The PE-aWARE (Pulmonary Embolism WArsaw REgistry) is an on-going single-centre prospective observational study of patients with confirmed acute pulmonary embolism (APE). Extensive data on consecutive patients with pulmonary embolism is collected and stored. The main objective is to collect and provide information on patients' characteristics, management, and outcome with the purpose of decreasing mortality in APE, the occurrence of bleeding, and the frequency of thromboembolic recurrences. Moreover, the PE-aWARE registry serves as a basis for creating predictive scores for clinicians which aid patient management. The study endpoints comprise clinically recognized (and objectively confirmed) recurrences of PE, major and minor bleeding complications classified according to the International Society on Thrombosis and Haemostasis classification, need for cardiopulmonary resuscitation or catecholamines, and death.

Eligibility Criteria

Inclusion Criteria: * objectively confirmed pulmonary embolism * Informed consent for the participation in the study, according to the requirements of the ethics committee Exclusion Criteria: * lack of consent

Contact & Investigator

Central Contact

Piotr Pruszczyk, Prof.

✉ piotr.pruszczyk@wum.edu.pl

📞 00 48 22 502 11 44

Principal Investigator

Piotr Pruszczyk, Prof.

STUDY DIRECTOR

Medical University of Warsaw

Frequently Asked Questions

Who can join the NCT03916302 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Pulmonary Embolism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03916302 currently recruiting?

Yes, NCT03916302 is actively recruiting participants. Contact the research team at piotr.pruszczyk@wum.edu.pl for enrollment information.

Where is the NCT03916302 trial being conducted?

This trial is being conducted at Warsaw, Poland.

Who is sponsoring the NCT03916302 clinical trial?

NCT03916302 is sponsored by Medical University of Warsaw. The principal investigator is Piotr Pruszczyk, Prof. at Medical University of Warsaw. The trial plans to enroll 1,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology